Skip to content
Wire frame hand with test tube

XenoTech expands access to Red Blood Cell Partitioning service for improved pharmacokinetics assessments

To help customers better investigate their compounds’ clearance in preclinical drug development, XenoTech has expanded in vitro service capabilities of its Kansas City, KS headquarters facility to include a Red Blood Cell (RBC) Partitioning study.

A RBC Partitioning study aims to determine the blood to plasma distribution ratio by comparing drug concentration in whole blood versus isolated plasma. Certain compounds are preferentially sequestered into red blood cells and therefore have a blood to plasma ratio that is greater than 1. This information can help a drug developer improve pharmacokinetic (PK) calculations which would otherwise assume a 1:1 blood to plasma ratio.

Find more details about the study design and deliverables on our Red Blood Cell Partitioning service page, or read more about our partnership with the Drug Development Solutions Center to complement our in vitro expertise with more than 50 years of in vivo ADME and radioisotope (RI) labeling experience.

Accompanying the launch of the new service at the Kansas City facility, nonclinical study director and research scientist Dr. Steven McGreal will be presenting a live webinar detailing study design and considerations as well as implications concerning PK calculations. The webinar will conclude with a live Q&A with webinar registrants, during which Dr. McGreal will be joined by Dr. Pallavi Limaye, Director of Scientific Conuslting.